REGNREGN
US • —
$623.54
P/E
15.20
PEG
3.45
FCF Yield
—
Rev Growth YoY
+5.9% YoY
Gross Margin
85.7%
Health Score
8/10
D/E Ratio
0.09
Confidence
LOW
Business Snapshot
Regeneron Pharmaceuticals is a biotechnology company that develops medicines for serious medical conditions, with its primary revenue driver being Eylea for wet age-related macular degeneration and other eye diseases, along with Dupixent for inflammatory conditions. The company operates in the highly competitive biopharmaceutical market and holds a strong position as a leader in ophthalmology and immunology through its proprietary technologies. Its financial scale is substantial, supported by a robust product portfolio that generates significant revenue, though specific total revenue and market capitalisation figures are not provided in this data set. A key defining characteristic of Regeneron is its deep scientific expertise and internal research capabilities, which have produced multiple blockbuster drugs and a strong pipeline.
Financial Health
Regeneron's financial health is robust, underpinned by exceptional profitability. The company boasts a gross margin of 85.7% and a healthy net margin of 29.6%, indicating strong pricing power and operational efficiency...
Risk Assessment
- EARNINGS QUALITY — The company has a strong record of beating estimates in 4 out of the last 4 quarters, which does not represent a current credibility risk but is a positive data point.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION DIVERGENCE — A DCF model could not be calculated due to unavailable free cash flow data, creating an information gap in assessing intrinsic value.
- INSIDER ACTIVITY — A net sell signal from insiders with 10 sells versus 0 buys in the last 90 days, which may indicate bearish sentiment from corporate leadership....
Regeneron's financial health is robust, underpinned by exceptional profitability. The company boasts a gross margin of 85.7% and a healthy net margin of 29.6%, indicating strong pricing power and operational efficiency. The balance sheet is conservative with a very low Debt/Equity ratio of 0.09x, and a strong liquidity position reflected in a current ratio of 4.13x, providing ample financial flexibility. While a specific free cash flow figure is not available, the strong net margin and low leverage suggest the company is likely a significant cash generator. Overall, this financial profile supports substantial reinvestment into R&D, potential for strategic acquisitions, and a low risk of financial distress.
- EARNINGS QUALITY — The company has a strong record of beating estimates in 4 out of the last 4 quarters, which does not represent a current credibility risk but is a positive data point. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - VALUATION DIVERGENCE — A DCF model could not be calculated due to unavailable free cash flow data, creating an information gap in assessing intrinsic value. - INSIDER ACTIVITY — A net sell signal from insiders with 10 sells versus 0 buys in the last 90 days, which may indicate bearish sentiment from corporate leadership.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives